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Proteins in the circulatory system mirror an individ-
ual’s physiology. In daily clinical practice, protein
levels are generally determined using single-protein
immunoassays. High-throughput, quantitative anal-
ysis using mass-spectrometry-based proteomics of
blood, plasma, and serum would be advantageous
but is challenging because of the high dynamic range
of protein abundances. Here, we introduce a rapid
and robust ‘‘plasma proteome profiling’’ pipeline.
This single-run shotgun proteomic workflow does
not require protein depletion and enables quantita-
tive analysis of hundreds of plasma proteomes
from 1 ml single finger pricks with 20 min gradients.
The apolipoprotein family, inflammatory markers
such as C-reactive protein, gender-related proteins,
and >40 FDA-approved biomarkers are reproduc-
ibly quantified (CV <20% with label-free quantifica-
tion). Furthermore, we functionally interpret a 1,000-
protein, quantitative plasma proteome obtained by
simple peptide pre-fractionation. Plasma proteome
profiling delivers an informative portrait of a person’s
health state, and we envision its large-scale use in
biomedicine.
INTRODUCTION
Blood, plasma, and serum are the predominant samples used for
diagnostic analyses in clinical practice and are available in bio-
banks from thousands of clinical studies (Ve´gva´ri et al., 2011).
The quantitative analysis of individual plasma proteins by immu-
noassays is used in daily clinical diagnostics. However, immuno-
assays have inherent limitations with regard to multiplexing,
their specificity for protein isoforms, and their incompatibility
with hypothesis-free investigations. Mass spectrometry (MS)-
based proteomics is a technology that could address all of these
limitations and that should be capable of discovering biomarkers
in this easily accessible body fluid (Anderson, 2014). However,
MS-based plasma proteomics is extremely challenging for a
number of reasons, most prominently the extremely large dy-
namic range of protein abundances (Anderson and Anderson,
2002; Omenn, 2005). There is also a lack of very reproducible,robust, and high-throughput proteomic workflows to identify
and verify potential biomarker in large cohorts. As a result,
only few novel biomarkers have been established—fewer than
1.5 per year in the 15 years before 2010 (Anderson, 2010)—
and this has generally been done by immunoassay-based tech-
nologies, such as prostate-specific antigen, one of the best
known biomarkers in medicine (Vihko et al., 1978).
Dramatic improvements in the technology of MS-based prote-
omics over the last few years (Cox andMann, 2011; Geiger et al.,
2010; Mun˜oz and Heck, 2014) have rekindled an interest in
plasma proteomics. Using such technology and combining it
with immunodepletion of high- andmedium-abundance proteins
as well as very extensive peptide fractionation methods, it has
now become possible to identify more than 1,000 (Addona
et al., 2011; Cao et al., 2012; Paczesny et al., 2010) or even
more than 5,000 proteins (Keshishian et al., 2015) in plasma.
However, immunodepletion may lead to biases because of
cross-reactions of the antibodies used or by proteins bound
to carrier proteins such as albumin (Bellei et al., 2011; Tu et al.,
2010). Furthermore, extensive pre-fractionation decreases
throughput, which is undesirable in clinical practice. Accord-
ingly, the paradigm in biomarker discovery by MS has been to
analyze a small number of samples in as much depth as
possible, whereas the verification phase was to be done on
larger cohorts but with targeted methods and a small number
of candidate markers. The final clinical test for a biomarker
identified by MS was to be performed with classical immunoas-
says (Anderson et al., 2009; Surinova et al., 2011). Although this
scheme is practical with current technology, it is very laborious
and loses much of the promise of systemwide and unbiased
investigation of the plasma proteome. Using another approach,
Liu et al. (2015) constructed a list of plasma peptide transitions,
which they used to interpret the signals in sequential window
acquisition of all theoretical MS (SWATH) runs of plasma
samples of twins. In this way, the contribution of heritable and
environmental changes to the plasma proteome could be
distinguished.
In contrast to previous approaches, we here focused on
developing a robust and highly streamlined shotgun plasma
proteomics workflow. For the MS readout, we used very short
liquid chromatography (LC)-MS/MS gradients and recent ad-
vances in label-free quantification (Cox et al., 2014). We hy-
pothesized that the resulting ‘‘plasma proteome profile’’ would
have a high yield of information about the health state of an
individual and that it can be obtained for a large number of
clinical samples.Cell Systems 2, 185–195, March 23, 2016 ª2016 The Authors 185
RESULTS
Rapid, Robust, and Highly Reproducible Plasma
Proteomic Workflow
Past efforts in shotgun plasma proteomics endeavored to maxi-
mize protein identifications, whereas generally less emphasis
was placed on quantitative accuracy or throughput. Here we
wished to develop a convenient workflow, from sample prepara-
tion to data analysis, that can potentially be used in a clinical
context. We reasoned that such a workflow should be rapid,
optimal for high-throughput, robust, and highly reproducible.
Therefore, it should minimize all preparation and analysis steps,
while still quantifying clinically interesting proteins accurately.
With this in mind, we decided to omit any depletion steps of
high-abundance plasma proteins.
Building on the recently described in-StageTip (iST) method
(Kulak et al., 2014), we further streamlined the procedure for
plasma (Experimental Procedures; Figure 1A). Starting with 1 ml
of plasma from a single finger prick, all preparation steps were
performed in a single reaction vial. Using ordinary amounts of
digestion enzymes, we found that adequate protein digestion
had already occurred after 1 hr (protein coefficients of variation
[CVs] and tryptic missed cleavage rates were similar to overnight
digestion; Table S1). Peptides were then eluted and ready for
LC-MS/MS analysis. The entire up-front procedure took less
than 2 hr and can readily be performed in a 96-well format and
automated in a liquid handling platform, if desired.
Starting with single-run gradient times typical of proteomics
experiments, we successively reduced them to determine the
maximum information content per unit time. We found that
the number of identified proteins decreased very slowly with
decreasing time, down to 20 min (only 12 additional identified
protein groups in 100 min versus 20 min gradients; Table S1).
Below this time, loading and equilibration times become domi-
nant, and therefore we chose 20 min gradients as our standard
(33 min between injections, about 50 samples/day). The combi-
nation of optimized sample preparation and LC setup allowed for
hundreds of plasma proteome analyses, whereas previously
clogging of columns was a common occurrence with plasma
samples.
We used MaxQuant for quantitative label-free analysis of
the LC-MS/MS data (Cox et al., 2014; Cox and Mann, 2008)
and for transferring peptide identifications from one LC run to
other LC runs in which the peptide was not sequenced (‘‘match
between runs’’). In combination with a matching library consist-
ing of undepleted plasma of ten different individuals as well
as plasma depleted of the 20 highest abundant proteins, this
boosted protein identification by 39% (Experimental Proce-
dures; Figures S1A and S1B). Of the 347 protein groups identi-
fied in total in the 20 min gradients, 285 were detected in all
ten individuals (Figures S1C and S1D). The entire workflow,
including the finger-prick procedure and the data analysis, takes
less than 3 hr (Figure 1A).
Accuracy of Label-free Quantification of the Plasma
Proteome
To investigate the quantitative reproducibility of our workflow
(intra-assay variability), we sampled blood by venous puncture
from one individual and harvested plasma after centrifugation.186 Cell Systems 2, 185–195, March 23, 2016 ª2016 The AuthorsWe performed the entire workflow 15 separate times on 1 ml ali-
quots of this stock and correlated protein abundances across
the whole measuring range of each of the replicates. The mean
R2 correlation value of the quantified protein signals between
individual replicates was excellent at 0.980, with a range of
0.966–0.994 (Figure 1B, excluding keratins; Table S2). We per-
formed 96 blood plasma analyses using multiplexed preparation
on a liquid handling robot and short measurement times (5 hr and
51 hr in total, respectively) and achieved a mean R2 value of 0.97
(Figure S2).
On average, 284 ± 5 different proteins were quantified (total
313): the large majority in all 15 samples and only 3% uniquely
in single LC runs (Figure 1C). We picked six well-characterized
plasma proteins across a million-fold abundance range and
found that quantification was highly reproducible (Figure 1D).
We compared different conditions by the proportion of proteins
with CVs less than 20%, because this is a commonly used cutoff
for in vitro diagnostic assays (U.S. Department of Health and
Human Services, Food and Drug Administration, Center for
Drug Evaluation and Research, Center for Veterinary Medicine,
2001). Notably, 67% of quantified proteins were within the
20% cutoff range, and 30% had CVs below 10% (Figure 1E).
To determine the variability caused by LC-MS/MS analysis
alone (analytical variability), peptides from one sample prepara-
tion were injected and measured 15 times. This resulted in only
slightly better reproducibility (71% with a CV less than 20%
and 37% with a CV less than 10%), indicating that up-front
sample preparation contributed little to overall quantitative vari-
ability (Figure 1F). A notable exception to this trend were certain
keratin proteins, which had very small analytical variability
but sometimes had a large quantitative difference between
repeated analysis of the same sample. This is readily explained
by contamination with exogenous keratins during sample prep-
aration. Nevertheless, it is clinically relevant, because we found
that plasma proteomes of the same person clustered together
much better after excluding keratins and other proteins intro-
duced by sample processing such as hemoglobins (see below).
Intra- and Inter-individual Variability of the Plasma
Proteome
The high-throughput of our workflow allowed us to extensively
characterize the quantitative variation within and between indi-
viduals. To determine inter-individual variability, we performed
finger pricks on one person four times a day over 8 consecutive
days and analyzed all 32 blood proteomes with less than 24 hr of
measuring time. This revealed stability of the plasma proteome
over time (55% of proteins below 20% CV; Figure 2A). The pro-
teins with large CVswere the aforementioned keratins, as well as
high-abundance erythrocyte-specific proteins. The latter are
caused by a slightly different extent of erythrocyte lysis during
plasma preparation or by contamination of plasma with erythro-
cytes during plasma harvesting.
To determine inter-individual variability, we harvested plasma
from five female and five male donors in triplicate by finger
pricks. The average R2 value within the technical workflow tripli-
cates was 0.976, excluding keratins and erythrocyte-specific
protein groups. For CVs of the technical replicates of all individ-
uals, see Table S3. Of 345 proteins quantified, only a minority
was under the CV cutoff. This indicates that overall, the plasma
Figure 1. Technological Aspects of Plasma Protein Profiling
(A) Schematic depiction of theworkflow. Blood volumes of 5 ml are routinely used to harvest 1 ml of plasma. Theworkflow is based on the iST protocol and consists
of denaturation, reduction, alkylation of cysteines, short 1 hr enzymatic digestion, and purification of peptides. Automation for liquid handling platforms is also
indicated. Peptides are separatedwith optimized short 20min HPLC gradients andmeasured online by LC-MS/MS. Data analysis is performed byMaxQuant and
Perseus, which deliver information about hundreds of plasma proteins that could reflect an individual’s state as symbolized by the plasma proteome profiles.
(B) Color-coded R2 values for the binary comparison of 15 technical workflow replicates. R2 values up to 0.994 demonstrate high reproducibility.
(C) Frequency of protein quantification, which was present in all 15 workflow replicates, in 10–14, in 2–9, or only in 1.
(D)Reproducibilityof theLFQ intensitiesof sixproteinscoveringnearlysixordersofmagnitude for15workflowreplicates. The line represents themeanvalues forALB
(serum albumin), HP (haptoglobin), APOC3 (apolipoprotein C-III), PROS1 (vitamin K-dependent protein S), F11 (coagulation factor XI), and VNN1 (pantetheinase).
(E) To determine the intra-assay variability, CVs of all quantified proteins were calculated for the 15 workflow replicates and are plotted according to their
abundance. Proteins with CVs < 20%are colored in blue and thosewith CVs > 20% in gray. HBB, hemoglobin subunit beta. SHBG, sex hormone-binding globulin;
SAA1, serum amyloid A-1 protein.
(F) Fifteen repeated injections were used to determine the analytical variability, which includes variability of the LC-MS/MS analysis.proteome has much higher inter- than intra-individual variability
(19% and 55% of proteins within a CV of 20%, respectively; Fig-
ure 2B). These general trends have been observed previously (for
a recent example, see Liu et al., 2015). Here they suggest that ourlabel-free workflow is well suited to capture the natural or path-
ological variation of protein levels between individuals.
To directly test this notion, we asked if we could discern sys-
tematic differences between the plasma proteomes of womenCell Systems 2, 185–195, March 23, 2016 ª2016 The Authors 187
Figure 2. Intra- and Inter-individual Variability of the Plasma Proteome
(A) Intra-individual variability was assessed by finger pricks four times per day for 8 days, and CVs for all quantified proteins were calculated. Proteins with
CVs < 20% are colored in blue and those with CVs > 20% in gray.
(B) Inter-individual variation of five women and five men.
(C) Female and male proteomes in one-dimensional PCA.
(D) Proteins and their contribution to the gender separation.
(E) Direct comparison of female subject 4 (F4) andmale subject 5 (M5) depicts the extreme difference of PZP between women andmen against the background of
all other quantified proteins.
(F) Volcano plot of female against male proteomes (x axis, fold change of females to males serving as t test difference; y axis, p value). The black curves show the
threshold for statistical significance, where we used a false discovery rate of 5% and an S0 of 0.8.
(G) LFQ intensities for PZP in all ten individuals.and men, a question that to our knowledge has not been ad-
dressed by shotgun proteomics before. Indeed, one-dimen-
sional principal-component analysis (PCA) was already sufficient
for complete separation (Figure 2C). Inspection of the drivers of
the PCA separation revealed that several of them are known to
be regulated by estrogen (Figure 2D) (Christensen et al., 1989;
Ottosson et al., 1981; Sand et al., 1985). Direct comparison of
the plasma proteome profiles of a woman and a man shows
that pregnancy zone protein (PZP) and sex hormone-binding
globulin (SHBG) are of high absolute abundance in the plasma
proteome of women and can be as high as 1% of human serum
albumin (Figure 2E). This suggests a functional role in plasma,
and indeed, SHBG binds estrogen, whereas PZP traps prote-
ases (Figure 2F). On average, PZP levels were 33-fold higher in
women compared with men. Furthermore, two women had 10-
to 100-fold higher levels than the other three, likely because of
highly elevated levels of estrogen (Figure 2G).Rapid Assessment of Sample Quality by Plasma
Proteomes
A frequently discussed issue in plasma proteomics as well as in
clinical laboratory medicine is the potentially deleterious effects
of inconsistent sample handling, such as variable time between
blood taking and workup. We reasoned that our rapid and highly188 Cell Systems 2, 185–195, March 23, 2016 ª2016 The Authorsreproducible workflowmight also allow the determination of pro-
tein markers of sample quality.
In clinical practice, a certain degree of hemolysis is not uncom-
mon. Starting from our observation that high-abundance eryth-
rocyte-specific proteins often showed high variability (Figures
2A, 2B, and 3A), we deliberately spiked in increasing amounts
of erythrocyte lysates to pure plasma. We obtained a proportion-
ate increase of erythrocyte-specific proteins, specifically, hemo-
globin subunits alpha, beta, delta, and carbonic anhydrase 1.
Notably, these proteins increased linearly (R2 = 0.99), and even
an admixture of 1 in 10,000 could easily be spotted (Figure 3B).
This demonstrates that plasma proteome profiling readily indi-
cates even small amounts of cellular contamination, in which
case the values of pertinent proteins could be disregarded or
corrected. The importance of this analysis step is illustrated by
triplicate plasma proteome analysis, in which the samples from
individual donors clustered together much more tightly in PCA
when keratins and prominent red blood cell proteins were
removed (Figure S3).
The blood coagulation system is primed for clotting in case of
injury and wound repair. Although serum is harvested by
inducing coagulation, harvesting of plasma requires addition of
appropriate amounts of anticoagulants. Our plasma proteome
profile contained many proteins with a function in the coagula-
tion cascade, and we next evaluated the coordinate behavior
of these proteins as a quality control for appropriate plasma
preparation. Plasma from each of the fingers of one individual
was processed (Experimental Procedures). The levels of fibrin-
ogen alpha (FGA), fibrinogen beta (FBA), and fibrinogen gamma
(FGG) were lower in two of the samples. In addition, platelet
basic protein (PPBP) and platelet factor 4 variant (PF4V1), which
are released from activated blood platelets, were increased only
in these same samples (Figure 3C), suggesting that partial coag-
ulation had occurred. To test this hypothesis, we collected
plasma and serum from two individuals and carried out sample
preparation in triplicates. Indeed, levels of FGA, FGB, and FGG
were much lower and levels of PPBP and PF4V1 much higher
in serum compared with plasma (Figure 3D).
These observations prompted us to investigate coagulation
anderythrocyte status in optimally preparedplasma. For this pur-
pose, we obtained reference samples from a blood bank, which
hadgone throughanextremely rigorous sample collectionproce-
dure (Experimental Procedures). They had very low and constant
levels of red blood cell-specific proteins, and none had evidence
of partial clotting. Although our plasma samples were also virtu-
ally coagulation free, this is in our experience not always the
case with samples obtained from clinical studies (Figure S4).
Quantification of Clinically Interesting Markers in Short
Gradients
Apolipoproteins are functional blood proteins involved in lipid
homeostasis. They therefore reflect an individual’s metabolic
status, and some of them are classical markers of cardiovascular
risk and metabolic disorders such as diabetes (Jenkins et al.,
2014; Jensen et al., 2014). We quantified 15 apolipoproteins at
each of 32 different time points in one individual. Apolipopro-
tein-a (LPA) had the strongest variation (CV = 20%), whereas
APOB had the lowest (CV = 6%). The distribution of LPA levels
in the population is skewed toward zero, with most individuals
having low LPA levels but some (20%) having higher levels.
The successful quantification of the apolipoproteins in 32 plasma
proteomes demonstrates the feasibility of a longitudinal mea-
surement of risk factors known to be associated with an individ-
ual’s propensity for certain diseases (Figure 3E).
Some of the apolipoproteins have allelic variants occurringwith
high frequency in populations that can easily be detected by MS
(Krastins et al., 2013; Martı´nez-Morillo et al., 2014). The apolipo-
protein allele APOE4 in the homozygous form is the largest known
risk factor for late-onset Alzheimer’s diseasewith a 10-fold higher
risk compared with the homozygous APOE3 form (Tanzi, 2012).
APOE4 has an arginine at position 112 instead of a cysteine resi-
due inAPOE2andAPOE3. In the20minLC-MS/MSdata,wewere
able to clearly distinguish between the peptides LGADMEDVR
(APOE4) and LGADMEDVCGR (APOE2, APOE3). In our group of
ten individuals, two had one APOE4 allele (Figures 3F and 3G).
The second allele was either an APOE3 or the APOE2 allele.
Serum amyloid A-1 protein (SAA1) and C-reactive protein
(CRP) are acute phase proteins that are routinely measured in
the clinic. Both are correlated with inflammatory states, and
chronic elevation is strongly associated with increased risk for
future cardiovascular events (Hua et al., 2009; Wilson et al.,
2008). We found that their expression levels varied up to 1,000-
fold among the ten individuals, and in a correlated manner (R2 =
0.6; Figures 3H and 3I). In the plasma proteome with the highestlevels of SAA1 andCRP, these are by far the largest differences to
the plasma proteomes of the other healthy individuals, and this is
presumably caused by recovery from a common cold (Figure 3J).
Next, we asked if our rapid proteome profiles contained infor-
mation on any further known biomarkers. We scanned the raw
data of the 15 technical workflow replicates to calculate the
CVs for Food and Drug Administration (FDA)-cleared or FDA-
approved biomarkers, as listed Anderson (2010). In total, 49
FDA-approved biomarkers were present in this data set (46
quantified in all 15 workflow replicates); 41 of them had CVs of
less than 20%, and 28 had CVs even less than 10% (Figure 3K).
When dividing these FDA-approved biomarkers into different
classes (Anderson, 2010), 45 fell into ‘‘act in plasma,’’ 2 into ‘‘tis-
sue leakage,’’ and 1 into ‘‘receptor ligand,’’ and 1 was lysozyme,
which had not been assigned to any category. The 20 min gradi-
ents already covered 45 of a total of 54 proteins among the ‘‘act
in plasma’’ biomarkers. Interestingly, 42 of themwere among the
180 highest abundance proteins, whereas the next 133 proteins
contained only 7 known biomarkers (Figure 4A; Table S2).
Plasma Protein Epitope Signature Tags as Internal
Standards for Protein Quantification
In clinical applications, quantification is almost always performed
with internal standards. To add this capability to our fast work-
flow, we investigated the use of stable isotope labeling of amino
acids in cell culture (SILAC)-protein epitope signature tags
(PrESTs), which are recombinant expressed stable isotope-
labeled protein fragments. This approach has the advantage
that it controls for digestion efficiency, alkylation rate, and other
workflow aspects and that a ‘‘master mix’’ of dozens of proteins
of interest can be readily prepared and quantified (Edfors et al.,
2014; Zeiler et al., 2012). We used APOA1, APOA4, APOB,
APOE, and SHBG to construct a master mix for quantification
of multiple plasma proteins in short gradients. Samples from
ten individuals were prepared in triplicate and measured (Fig-
ure S5, Table S4). This resulted in low CVs for these proteins
(APOA1 = 2.3%, APOA4 = 3.8%, APOB = 5.3%, APOE = 3.8%,
and SHBG = 14.7%). Optimized targeted methods applied to
peptides resulting from the PrESTs could improve these CVs
even further.
A Quantitative Proteome of 1,000 Plasma Proteins
The above experiments highlight the value of quantifying hun-
dreds of proteins in a very short analysis time. To obtain esti-
mates of abundances for a deeper plasma proteome, we used
a combination of peptide pre-fractionation, a matching library
consisting of depleted plasma, and 100 min high-performance
LC (HPLC) gradients. With 16 hr of measurement time, we iden-
tified 1,040 proteins in non-depleted plasma, of which 965 had
label-free protein quantification (LFQ) values. Although MS sig-
nals for these proteins span more than six orders of magnitude,
the majority of them were confined to a 100-fold abundance
range (Figure 4B). The deep proteome data can be assessed
in Table S5 and in the MaxQB database (Schaab et al., 2012),
which also displays the mass spectrometric evidence and
MS/MS transitions for all identified peptides.
Unexpectedly, the deep plasma proteome contained only
14 additional FDA-approved biomarkers compared with the
49 already found in the 20 min gradients. Nine of them wereCell Systems 2, 185–195, March 23, 2016 ª2016 The Authors 189
Figure 3. Quantification of Clinically Interesting Proteins
(A) Scatterplot of repeated finger pricks of one individual (replicate 2 versus replicate 3) showing that erythrocyte-specific proteins were elevated as a group.
HBA1, hemoglobin subunit alpha; HBB, hemoglobin subunit beta; HBD, hemoglobin subunit; CA1, carbonic anhydrase 1.
(B) Spike-in of erythrocytes into plasma resulting in an increase of these proteins.
(C) Blood was processed from ten different fingers of one individual after finger pricking, and LFQ intensities of FGA, FGB, FGG, PPBP, and PF4V1 are plotted. In
samples 1 and 2, fibrinogens are decreased, whereas platelet-specific proteins are increased.
(D) FGA, FGB, and FGG levels are decreased, and PPBP as well as PF4V1 levels are elevated in serum compared with plasma in two individuals.
(E) Fifteen apolipoproteins were quantified without anymissing value after longitudinal collection of 32 plasma samples of one individual (four finger pricks per day
over 8 days).
(F) The peptide LGADMEDVR is specific for the APOE4 allele and was present and quantified in two of ten individuals.
(G) Presence of at least one APOE2 or APOE3 allele in all ten individuals.
(legend continued on next page)
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Figure 4. FDA-Approved Biomarker and
Deep Plasma Proteomics
(A) Distribution of proteins quantified in the
20 min gradients of the 15 workflow replicates.
FDA-approved biomarkers are color coded. The
dashed line separate the regions densely popu-
lated and sparsely populated by biomarkers.
(B) LFQ intensities of 965 proteins quantified after
separating peptides into eight fractions. The yel-
low rectangle encloses a 100-fold range, which
contains the majority of the measured plasma
proteome.
(C) Correlation of LFQ intensities of the deep
plasma proteome data set and absolute concen-
trations from the Plasma Proteome Database.
(D) UniProtKB keyword annotations and their
enrichment along the whole abundance range as
determined by 1D enrichment (see main text).
Exemplary proteins contributing to keywords are
highlighted in red. APOC3, apolipoprotein C-III;
F12, coagulation factor XII; C2, complement
C2; MASP1, Mannan-binding lectin serine prote-
ase 1; ITIH4, inter-alpha-trypsin inhibitor heavy
chain H4; HNRNPDL, heterogeneous nuclear
ribonucleoprotein D-like; PSMA5, proteasome
subunit alpha type 5.classified as ‘‘tissue leakage,’’ only 4 as ‘‘act in plasma,’’ and 1
was not assigned to any category. A depth of 450 plasma pro-
teins would be sufficient to cover 87% of the FDA-approved bio-
markers present in our deep data set according to Anderson
(2010).
The fact that we did not use protein depletion allowed us to
investigate the quantitative nature of the plasma proteome. Bio-
informatics analysis revealed that 457 of all quantified proteins
had an extracellular annotation and 651 an intracellular one,
with 221 overlapping proteins. Interestingly, the 430 proteins
with exclusive intracellular annotation, which also have an inde-
pendent abundance estimate in the Plasma Proteome Database
(Nanjappa et al., 2014), are almost completely excluded from the
top three order of magnitudes of protein abundance (Figure 4C).
These proteins are likely of tissue origin and have been released
by normal tissue damage, without necessarily having a function
in blood. In contrast to the deep proteome, these intracellular
proteins were largely absent in the 20 min measurements (25
of 313 proteins; Table S2). Reassuringly, 91% of proteins identi-
fied in plasma by us had also been identified in at least one of the
studies collected in the PeptideAtlas repository (Farrah et al.,
2014). In the absence of MS-derived quantitation of a deep,
non-depleted proteome, we turned to the Plasma Proteome
Database, which lists absolute concentrations of 597 of the
proteins that are also quantified in our data set. Although these
concentrations derive from the literature from awide variety of in-(H) Variation of the acute phase protein SAA1 in ten individuals.
(I) Variation of the inflammatory marker CRP in the same ten individuals.
(J) Direct comparison of two individuals to visualize the magnitude of SAA1 and
(K) The CVs of 49 FDA-approved biomarkers from 15 workflow replicates as a fudividuals, health states, and quantification methods, we found a
reasonable correlation, with an R2 value of 0.53. This analysis
also confirmed that we had quantified many proteins of clinical
interest in the lower abundance range, such as the plasma pro-
tein ferritin (FTL) (12 ng/ml), which is widely used to diagnose
dysregulation of iron homeostasis, or the cytokine macrophage
migration inhibitory factor (MIF) (10 ng/ml). A total of 183 proteins
in our data set have reported concentrations below 10 ng/ml.
To bioinformatically analyze the functional nature of the
plasma proteome, we used the ‘‘1D annotation’’ algorithm in
the MaxQuant software (Cox and Mann, 2008, 2012), to assign
UniProtKB keywords to distinct abundance ranges. This resulted
in 58 statistically significant features (Table S6). Classical char-
acteristics of the plasma proteome were typically located in
the high-abundance range. These include ‘‘glycation,’’ ‘‘immu-
noglobulin,’’ and ‘‘chylomicrons,’’ which are expected because
functional plasma proteins are typically glycated, a large propor-
tion of functional plasma proteins are antibodies, and apolipo-
proteins are the structural components of chylomicrons. In
the low-abundance tail of the distribution, we found highly abun-
dant intracellular complexes such as the proteasome as well as
RNA-binding and processing proteins. ‘‘Phosphoprotein’’ was
situated close to themiddle of the distribution, and above ‘‘mem-
brane,’’ ‘‘cytoplasm,‘‘ and ‘‘nucleus,‘‘ presumably because most
intracellular proteins have by now been shown to be phosphor-
ylatable, in addition to some of the extracellular ones. TheCRP in the background of the other quantified plasma proteins.
nction of protein abundance rank.
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mean of functionally important Gene Ontology annotated biolog-
ical processes, such as ‘‘protein-lipid complex assembly,‘‘ ‘‘ste-
rol and cholesterol transport,‘‘ ‘‘acute phase response,‘‘ and
‘‘regulation of coagulation’’ processes all scored in the upper
third of the distribution, highlighting that these functions are
overwhelmingly carried out by high-abundance plasma proteins.
The above analysis can also be used to infer the likely function
or lack thereof of a protein found at a certain concentration in
normal plasma. For instance, the hormone-binding protein
SHBG is in the upper range of the plasma proteome, which cor-
relates well with its carrier function for an abundant circulating
hormone (Ottosson et al., 1981) (Figure 4D).
DISCUSSION
Using state-of-the-art shotgun proteomics technology, in partic-
ular the recently described iST preparation (Kulak et al., 2014),
Orbitrap instrumentation with very high sequencing speed
(Kelstrup et al., 2014; Scheltema et al., 2014), and advances in
label-free quantification (Cox et al., 2014), we here developed
a streamlined and robust workflow for shotgun plasma prote-
omics. Sample preparation steps are minimized without loss of
performance, and the procedure can be performed in 96-well
format by a liquid handling platform. In this way, hundreds of
plasma proteomes can be processed and sample preparation
is not a limiting step for plasma proteomics in our workflow.
We found that even extremely short measurements of 20 min still
allowed the identification of more than 300 proteins, which was
aided by a reference data set and the ‘‘match between runs’’
functionality. Accuracy and precision of the label-free workflow
were excellent with intra-assay correlation of about R2 = 0.98
and CVs smaller than 20% for the majority of quantified proteins.
Starting from only a finger prick of blood, the entire workflow,
including database search and label-free quantification, can be
performed in less than 3 hr. Previous plasma proteome studies
typically started from milliliter amounts of blood, used depletion,
and extensive pre-fractionation and therefore required days for
completion (Cao et al., 2012; Keshishian et al., 2015; Liu et al.,
2015; Such-Sanmartı´n et al., 2014). The ability to use small sam-
ple amounts makes blood testing much less invasive, improves
cost-efficiency, and is clinically attractive in many situations,
including the testing of infants as well as elderly patients (Bai
et al., 2013). Likewise, fast response time is frequently important
such as in the case of myocardial infarction. Our procedure uses
a very short digestion time (60 min), which could be reduced by
further optimization, so that the entire procedure could conceiv-
ably be performed in less than 1 hr.
Our very short LC-MS/MS runs contain nearly 50 proteins that
are already subject to FDA-approved diagnostic tests, whereas
the deep proteomeonly added fewadditional ones. Furthermore,
the proportion of functional plasma proteins was very high, in
contrast to the lower abundance range, which was dominated
by tissue-derived ‘‘leakage proteins.’’ Nevertheless, the deeper
proteome still contained many proteins of known clinical signifi-
cance, and it is interesting to speculate whether the relative
paucity of approved biomarkers in this range is due to the greater
difficulties associated with studying these proteins. Even in the
short analysis runs, the lower half of the distribution has not yet
been associated with specific patient states. We suggest that192 Cell Systems 2, 185–195, March 23, 2016 ª2016 The Authorsmixtures of recombinant isotope-labeled protein fragments, so-
called SILAC-PrESTs (Edfors et al., 2014; Zeiler et al., 2012),
could routinely be added to plasma samples. This would enable
very high accuracy in absolute quantification for the discovery
and validation of such biomarkers at high-throughput.
Further throughput improvements can be achieved with
chemical labeling strategies, for instance with isobaric chemical
tags such as TMT (Thompson et al., 2003). For 10-plex encoding,
this could increase throughput to hundreds of patients per day.
This compares favorably with metabolomics studies, which are
already performed at large scale in plasma cohorts (Suhre
et al., 2011), while providing equally useful and complementary
information. Alternatively, TMT could be used to label patient
samples before peptide pre-fractionation. This should result in
deep proteome coverage, while keeping effective MS measure-
ment time reasonably short at 1–2 hr per patient and compatible
with large-scale studies.
The proteins characterized in our short workflow already
contain a plethora of useful information. For example, it was
easy to distinguish the gender of the donor and to obtain some
risk-associated genotype information. The spectrum of apolipo-
proteins, as well as inflammatory markers, was excellently quan-
tified, reflecting the cardiovascular and metabolic health state.
Unexpectedly, the global nature of shotgun proteomics supplies
us with valuable information about sample quality, which is not
tested in routine clinical practice but can influence test results
and medical decisions.
Asmentioned above, the current strategy in plasma biomarker
discovery by MS-based proteomics involves a narrowing down
and widening strategy: a small number of patients and controls
are analyzed in great depth with unbiased and relatively low-
throughput methods. Resulting potential biomarkers are then
envisioned to be validated with targeted MS-based methods or
classical immunoassays in much larger cohorts (Anderson,
2014; Keshishian et al., 2015; Surinova et al., 2011).
Here we suggest an additional strategy, which we term
‘‘plasma proteome profiling.’’ It consists of the measurement of
large numbers of plasma proteomes at the greatest possible
depth with streamlined and high-throughput technologies as
described in this paper. This allows us to retain one of the basic
attractions of unbiased, systemwide methodologies, namely,
that associations do not have to be predefined but emerge natu-
rally from ‘‘big data mining.’’ Although our current work is only a
first step in this direction, we believe that rapid development in
the underlying technology will make this strategy more and
more attractive. Given the low resource requirements, large
cohorts could be investigated in the future, and one can
even envision individuals routinely and repeatedly have their
plasma proteome profile recorded. These high-dimensional pro-
files could indicate current disease risk as well as efficacy of life-
style changes or pharmacological interventions and thereby
contribute to individual and public health.EXPERIMENTAL PROCEDURES
Tryptophan Fluorescence Emission Assay for Protein Quantification
Protein concentrations were determined after solubilizing of samples in 8 M
urea by tryptophan fluorescence emission at 350 nm using an excitation wave-
length of 295 nm. Tryptophan at a concentration of 0.1 mg/ml in 8 M urea was
used to establish a standard calibration curve (0–4 ml). From this, we estimated
that 0.1 mg/ml tryptophan is equivalent to the emission of 7 mg/ml of human pro-
tein extract, assuming that tryptophan on average accounts for 1.3% of the
human protein amino acid composition.
Blood Collection from Finger Pricks and Venous Blood Sampling
Blood was taken by lancets (Vitrex Sterilance Lite II) to obtain small quantities
of capillary blood, and 5 ml of blood was transferred by a pipette into a pipette-
tip-based centrifugal devices containing 0.56 ml 106 mM trisodium citrate (end
concentration 10.6 mM trisodium citrate, as commonly used in blood collec-
tion tubes). The pipette-tip-based centrifugal device was made by melting
the end of a pipette tip to seal it. When larger amounts of plasma were needed,
blood was taken by venipuncture using a commercially available winged infu-
sion set into collection tubes containing sodium citrate. The blood was centri-
fuged for 15 min at 2,0003 g, and plasma was harvested. Blood was sampled
from healthy donors, who provided written informed consent, with prior
approval of the ethics committee of the Max Planck Society.
Plasma taken by venipuncture was used to determine analytical and intra-
assay variability, because in this case, larger amounts of plasma (15 ml) were
needed.
Plasma for intra-individual variability was taken from one person by four
finger pricks (at 6 a.m., 9 a.m., 12 p.m., and 3 p.m.) per day for 8 days. To deter-
mine the inter-individual variability, blood was taken by finger pricking of ten
different individuals in triplicate (five women and five men), and samples
were randomized within the gender groups. Furthermore, blood was taken
from all ten fingers of one individual to one individual plasma and by venipunc-
ture from two individuals for the comparison of plasma and serum.
Highly reliable plasma samples (PlasmaRef Panels) were obtained from the
blood bank Blutspendedienst des Bayerischen Roten Kreuzes.
High-Abundance Protein Depletion for Building a Matching Library
A combination of two immunodepletion kits was used for optimal removal of
the 20 highest abundance plasma proteins with the purpose of establishing
a peptide library for matching between runs (Nagaraj et al., 2012). First we
used the Agilent Multiple Affinity Removal Spin Cartridge for removal of the
top six high-abundance proteins (albumin, IgG, IgA, antitrypsin, transferrin,
and haptoglobin), followed by ProteoPrep20 Plasma Immunodepletion Kit
for the 20 highest abundance proteins from human plasma (Albumin, IgG,
IgA, IgM, IgD, transferrin, fibrinogen, a2-macroglobulin, a1-antitrypsin, hapto-
globin, a1-acid glycoprotein, ceruloplasmin, apolipoprotein A-I, apolipopro-
tein A-II, apolipoprotein B, complement C1q, complement C3, complement
C4, plasminogen, and prealbumin). Both depletion steps were carried out ac-
cording to the manufacturer’s instructions. The depleted plasma was digested
and measured as described below. Raw data of the depleted plasma of one
individual and undepleted plasma of ten different individuals served as a ‘‘li-
brary’’ for matching between runs for the 20 min gradients.
Sample Preparation: Protein Digestion and iST Purification
Sample preparation was performed as described previously (Kulak et al., 2014)
with optimization for blood plasma as follows: 24 ml of SDC reduction and alkyl-
ation buffer (Kulak et al., 2014) were added to 1 ml of blood plasma. Themixture
was boiled for 10min to denature proteins. After cooling down to room temper-
ature, the proteolytic enzymes LysC and trypsin were added in a 1:100 ratio
(micrograms of enzyme to micrograms of protein). Digestion was performed
at 37C for 1 hr. Peptides were acidified to a final concentration of 0.1% tri-
fluoro-acetic acid (TFA) for SDB-RPS binding, and 20 mg was loaded on two
14-gauge StageTip plugs. Ethylacetate/1% TFA (125 ml) was added, and the
StageTips were centrifuged using an in-house-made StageTip centrifuge (a
centrifuge with identical specifications is available from Sonation) for up to
2,0003 g. After washing the StageTips using two wash steps of 100 ml ethyla-
cetate/1%TFAand one of 100 ml ddH2O/0.2%TFA consecutively, purified pep-
tides were eluted by 60 ml of elution buffer (80% acetonitrile, 19% ddH2O, 1%
ammonia) into auto sampler vials. The collected material was completely dried
using a SpeedVac centrifuge at 45C (Eppendorf, Concentrator plus). Peptides
were suspended in buffer A* (2% acetonitrile, 0.1% TFA) and afterward soni-
cated (Branson Ultrasonics, Ultrasonic Cleaner Model 2510).
For the deep plasma data set, 20 mg purified and digested plasma peptides
were fractionated using basic reversed-phase pre-fractionation. The peptideswere loaded onto a reversed-phase C18 column (1.9 mm Reprosil-Pur C18
beads; Dr. Maisch) and were eluted using an EASY-nLC 1000 system (Thermo
Fisher Scientific). A gradient was generated by using a dual-buffer systemwith
buffer A (ddH2O) and buffer B (ddH2O, 80% ACN) adjusted to pH 10 with
ammonium hydroxide. Peptides were separated and eluted from 5% B to
40%B in 50 min followed by a linear increase to 60%B in 10 min. The gradient
was followed by a 12 min washout with 60%–95% B. We concatenated the
46 collected fractions into 8 fractions (concatenation scheme: 1 + 9 + 17 +
25, 2 + 10 + 18 + 26, etc.). A total of 1 mg of each concatenated fraction was
loaded and measured by LC-MS/MS as described below.
Plasma samples from two individuals were dispensed into a 96-well plate
(48 samples for each individual), and the complete sample preparation, with
the exception of the centrifugation steps, was performed on an Agilent Bravo
liquid handling platform.
Design, recombinant expression, purification and quantification of plasma
PrESTs was as described in (Zeiler et al., 2012). Plasma PrESTs of the proteins
APOA1, APOA4, APOB, APOE, and SHBG were combined in a master mix,
which was added together with the SDC reduction and alkylation buffer to
the blood plasma. The subsequent steps for sample preparation workflow
are described above.
Ultra-High-Pressure LC and MS
Samples were measured using LC-MS instrumentation consisting of an EASY-
nLC 1000 ultra-high-pressure system (Thermo Fisher Scientific) coupled via a
nano-electrospray ion source (Thermo Fisher Scientific) to a Q Exactive HF
Orbitrap (Thermo Fisher Scientific) (Scheltema et al., 2014). Purified peptides
were separated on 40 cm HPLC-columns (internal diameter 75 mm; in-house
packed into the tip with ReproSil-Pur C18-AQ 1.9 mm resin; Dr. Maisch). For
each LC-MS/MS analysis, about 1 mg peptides were used for 20 min runs
and for each fraction of the deep plasma data set.
Peptides were loaded in buffer A (0.1% v/v formic acid) and eluted with a
linear 15 min gradient of 10%–50% of buffer B (0.1% v/v formic acid, 60%
v/v acetonitrile), followed by a 5min 98%wash at a flow rate of 450 nl/min. Col-
umn temperature was kept at 60C by a Peltier element-containing, in-house-
developed oven, and parameters were monitored in real time by the SprayQC
software (Scheltema and Mann, 2012). MS data were acquired with a Top5
data-dependent MS/MS scan method (topN method). Target values for the
full scan MS spectra were 3 3 106 charges in the 300–1,650 m/z range, with
a maximum injection time of 25 ms and a resolution of 60,000 at m/z 400.
A 1.5 m/z isolation window and a fixed first mass of 100 m/z was used for
MS/MS scans. Fragmentation of precursor ions was performed by higher en-
ergy C-trap dissociation with a normalized collision energy of 27 eV. MS/MS
ssans were performed at a resolution of 15,000 at m/z 200 with an ion target
value of 5 3 104 and a maximum injection time of 25 ms. Dynamic exclusion
was set to 15 s to avoid repeated sequencing of identical peptides.
Data Analysis
MS raw files were analyzed by MaxQuant software version 1.5.2.10 (Cox and
Mann, 2008), and peptide lists were searched against the human Uniprot
FASTA database (version June 2014) and a common contaminants database
by the Andromeda search engine (Cox et al., 2011) with cysteine carbamido-
methylation as a fixed modification and N-terminal acetylation and methionine
oxidations as variable modifications. The false discovery rate was set to 0.01
for both proteins and peptides with a minimum length of seven amino acids
and was determined by searching a reverse database. Enzyme specificity
was set as C-terminal to arginine and lysine as expected using trypsin as pro-
tease, and a maximum of two missed cleavages were allowed in the database
search. Peptide identification was performed with an allowed initial precursor
mass deviation up to 7 ppm and an allowed fragment mass deviation of 20
ppm. Matching between runs was performed with depleted plasma and unde-
pleted plasma of ten different individuals serving as a library. Proteins match-
ing to the reversed database were filtered out. LFQ was performed with a min-
imum ratio count of 1 (Cox et al., 2014).
Bioinformatics Analysis
All bioinformatics analyses were performed with the Perseus software of
the MaxQuant computational platform (Cox and Mann, 2008). Absolute quan-
tification of protein abundances was computed using peptide label-freeCell Systems 2, 185–195, March 23, 2016 ª2016 The Authors 193
quantification values, sequence length, and molecular weight (Cox et al.,
2014). For enrichment analysis, a false discovery rate of <0.02 after Benja-
mini-Hochberg correction was used.
Statistical Analysis
Reproducibility was analyzed by calculating R2 values for direct comparison of
the LFQ intensities of any two LC-MS/MS runs. CV values were calculated on
the basis of LFQ intensities. To determine the analytical and intra-assay vari-
ability, we used 15 raw data files, for intra-individual variation 32 files, and
for inter-individual variation 30 files, and triplicates for each individual were
combined before determining the CV.
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